Short commentary on empagliflozin and its potential clinical impact

Therapeutic Advances in Endocrinology and Metabolism

Volumn 6, Issue 2, 2015, Pages 68-81

  Hinnen, Deborah ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

empagliflozin; sodium glucose cotransporter type 2 inhibitors; type 2 diabetes mellitus

Indexed keywords

EMPAGLIFLOZIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

BLOOD PRESSURE; BODY WEIGHT; BONE DENSITY; CANCER RISK; CARDIOVASCULAR PARAMETERS; CELL FUNCTION; DRUG EFFICACY; DRUG SAFETY; FRACTURE; GENITAL TRACT INFECTION; GLYCEMIC CONTROL; HYPERGLYCEMIA; HYPERKALEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; URINARY TRACT INFECTION;

EID: 84930589774     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018815578599     Document Type: Review

References (70)

1. Abdul-Ghani M. DeFronzo R. (2008) Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 14: 782–790.
2. Babu A. (2013) Canagliflozin for the treatment of type 2 diabetes. Drugs Today (Barc) 49: 363–376.
3. Barendse S. Singh H. Frier B. Speight J. (2012) The impact of hypoglycaemia on quality of life and related patient-reported outcomes in type 2 diabetes: a narrative review. Diab Med 29: 293–302.
4. Barnett A. Mithal A. Manassie J. Jones R. Rattunde H. Woerle H. et al. (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2: 369–384.
5. Boehringer Ingelheim GmbH (2013) Pooled analysis data showed improvements in glycaemic parameters, body weight and blood pressure with investigational agent empagliflozin in adults with type 2 diabetes. Available at: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/24_september_2013empagliflozin.html (accessed 10 March 2014).
6. Bolinder J. Ljunggren Ö. Johansson L. Wilding J. Langkilde A. Sjöström C. et al. (2014) Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 16: 159–169.
7. Cefalu W. Leiter L. Yoon K. Arias P. Niskanen L. Xie J. et al. (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382: 941–950.
8. Chao E. (2012) Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes. Core Evid 7: 21–28.
9. Cherney D. Perkins B. Soleymanlou N. Maione M. Lai V. Lee A. et al. (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129: 587–597.
10. de Fronzo R. Eldor R. Abdul-Ghani M. (2013) Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 36(Suppl. 2): S127–S138.
11. de Fronzo R. Lewin A. Patel S. Liu D. Kaste R. Woerle H. et al. (2015) Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 38: 384–393.
12. Ehrenkranz J. Lewis N. Kahn C. Roth J. (2005) Phlorizin: a review. Diabetes Metab Res Rev 21: 31–38.
13. European Medicines Agency (2012) Forxiga (dapagliflozin). EMA Assessment Report. Procedure no. EMEA/H/C/002322. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002322/WC500136024.pdf (accessed 10 March 2014).
14. European Medicines Agency (2014 a) Forxiga (dapagliflozin). Summary of product characteristics (October 2014). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002322/WC500136026.pdf (accessed 10 March 2015).
15. European Medicines Agency (2014 b) Invokana (canagliflozin). Summary of product characteristics (September 2014). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002649/WC500156456.pdf (accessed 10 March 2015).
16. European Medicines Agency (2014 c) Jardiance (empagliflozin). CHMP Assessment Report (March 2014). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002677/WC500168594.pdf (accessed 10 March 2015).
17. European Medicines Agency (2014 d) Jardiance (empagliflozin). Summary of product characteristics (June 2014). Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002677/human_med_001764.jsp&mid=WC0b01ac058001d124 (accessed 10 March 2015).
18. European Medicines Agency (2014 e) Summary of the risk management plan (RMP) for Jardiance (empagliflozin) (April 2014). Available at: http://www.fimea.fi/download/27456_Jardiance_RMP_summary-EN.pdf (accessed 10 March 2015).
19. Ferrannini E. Muscelli E. Frascerra S. Baldi S. Mari A. Heise T. et al. (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124: 499–508.
20. Ferrannini E. Ramos S. Salsali A. Tang W. List J.F. (2010) Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33: 2217–2224.
21. Gangadharan Komala M. Mather A. (2014) Empagliflozin for the treatment of type 2 diabetes. Expert Rev Clin Pharmacol 7: 271–279.
22. Geerlings S. Fonseca V. Castro-Diaz D. List J. Parikh S. (2014) Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract 103: 373–381.
23. Grempler R. Thomas L. Eckhardt M. Himmelsbach F. Sauer A. Sharp D. et al. (2012) Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14: 83–90.
24. Hach T. Gerich J. Salsali A. Kim G. Hantel S. Woerle H. et al. (2013) Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): pooled data from four pivotal phase III trials. Abstract 69-LB. Diabetes 62(Suppl. 1A): LB19.
25. Han S. Hagan D. Taylor J. Xin L. Meng W. Biller S. et al. (2008) Dapagliflozin, a selective SGLT 2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57: 1723–1729.
26. Häring H. Merker L. Seewaldt-Becker E. Weimer M. Meinicke T. Broedl U. et al. (2014) Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 37: 1650–1659.
27. Häring H. Merker L. Seewaldt-Becker E. Weimer M. Meinicke T. Woerle H. et al. (2013) Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 36: 3396–3404.
28. Inzucchi S. Zinman B. Wanner C. Ferrari R. Fitchett D. Hantel S. et al. (2015) SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 12: 90–100.
29. Jabbour S. (2014) SGLT 2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem. Postgrad Med 126: 111–117.
30. Johnsson K. Ptaszynska A. Schmitz B. Sugg J. Parikh S. List J. (2013 a) Urinary tract infections in patients with diabetes treated with dapagliflozin.J Diabetes Complications 27: 473–478.
31. Johnsson K. Ptaszynska A. Schmitz B. Sugg J. Parikh S. List J. (2013 b) Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 27: 479–484.
32. Kim G. Gerich J. Salsali A. Hach T. Hantel S. Woerle H. et al. (2013) Empagliflozin (EMPA) increases genital infections but not urinary tract infections (UTIs) in pooled data from four pivotal phase III trials. Abstract 74-LB. Diabetes 62(Suppl. 1): LB21.
33. Kohan D. Fioretto P. Tang W. List J. (2014) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85: 962–971.
34. Kovacs C. Seshiah V. Swallow R. Jones R. Rattunde H. Woerle H. et al. (2013) Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16: 147–158.
35. Lamos E. Younk L. Davis S. (2014) Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs 23: 875–882.
36. Lewin A. DeFronzo R. Patel S. Liu D. Kaste R. Woerle H. et al. (2015) Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care 38: 394–402.
37. Macha S. Rose P. Mattheus M. Cinca R. Pinnetti S. Broedl U. et al. (2014) Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. Diabetes Obes Metab 16: 118–123.
38. McCrimmon R. Evans M. Jacob R. Fan X. Zhu Y. Shulman G. et al. (2002) AICAR and phlorizin reverse the hypoglycemia-specific defect in glucagon secretion in the diabetic BB rat. Am J Physiol Endocrinol Metab 283: E1076–E1083.
39. Merovci A. Solis-Herrera C. Daniele G. Eldor R. Fiorentino T. Tripathy D. et al. (2014) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124: 509–514.
40. Neal B. Perkovic V. de Zeeuw D. Mahaffey K. Fulcher G. Stein P. et al. (2013) Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) – a randomized placebo-controlled trial. Am Heart J 166: 217–223 e211.
41. Nicolle L. Capuano G. Fung A. Usiskin K. (2014) Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med 126: 7–17.
42. Nigro S. Riche D. Pheng M. Baker W. (2013) Canagliflozin, a novel SGLT 2 inhibitor for treatment of type 2 diabetes. Ann Pharmacother 47: 1301–1311.
43. Nyirjesy P. Sobel J. Fung A. Mayer C. Capuano G. Ways K. et al. (2014) Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 30: 1109–1119.
44. Perkins B. Cherney D. Partridge H. Soleymanlou N. Tschirhart H. Zinman B. et al. (2014) Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 37: 1480–1483.
45. Polidori D. Mari A. Ferrannini E. (2014) Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia 57: 891–901.
46. Ptaszynska A. Hardy E. Johnsson E. Parikh S. List J. (2013) Effects of dapagliflozin on cardiovascular risk factors. Postgrad Med 125: 181–189.
47. Ridderstråle M. Andersen K. Zeller C. Kim G. Woerle H. Broedl U. (2014) Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2: 691–700.
48. Ridderstråle M. Svaerd R. Zeller C. Kim G. Woerle H. Broedl U. (2013) Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT 2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovasc Diabetol 12: 129.
49. Roden M. Weng J. Eilbracht J. Delafont B. Kim G. Woerle H. et al. (2013) Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 1: 208–219.
50. Rodríguez-Gutiérrez R. Gonzalez-Saldivar G. (2014) Canagliflozin. Cleve Clin J Med 81: 87–88.
51. Rosenstock J. Jelaska A. Frappin G. Salsali A. Kim G. Woerle H. et al. (2014) Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 37: 1815–1823.
52. Rosenstock J. Jelaska A. Kim G. Broedl U. Woerle H. (2013) Empagliflozin as add-on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated (T2DM). Abstract 1102-P. Diabetes 62(Suppl. 1): A285.
53. Rosenwasser R. Sultan S. Sutton D. Choksi R. Epstein B. (2013) SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes 6: 453–467.
54. Rossetti L. Smith D. Shulman G. Papachristou D. DeFronzo R. (1987) Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79: 1510–1515.
55. Santer R. Calado J. (2010) Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 5: 133–141.
56. Scheen A. (2014) Evaluating SGLT 2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol 10: 647–663.
57. Seaquist E. Anderson J. Childs B. Cryer P. Dagogo-Jack S. Fish L. et al. (2013) Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 36: 1384–1395.
58. Sinclair A. Bode B. Harris S. Vijapurkar U. Mayer C. Fung A. et al. (2014) Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord 14: 37.
59. Stenlöf K. Cefalu W. Kim K. Alba M. Usiskin K. Tong C. et al. (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15: 372–382.
60. Tikkanen I. Narko K. Zeller C. Green A. Salsali A. Broedl U. et al. (2015) Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 38: 420–428.
61. US Food and Drug Administration (2013) Invokana (canagliflozin) tablets. NDA 204042. FDA Briefing Document (10 January 2013). Rockville, MD: US Food and Drug Administration.
62. US Food and Drug Administration (2014 a) Farxiga (dapagliflozin) label (January 2014). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/​2014/202293s003lbl.pdf. (accessed 1 August 2014)
63. US Food and Drug Administration (2014 b) Invokana (canagliflozin) label (May 2014). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204042s002lbl.pdf (accessed 10 March 2015).
64. US Food and Drug Administration (2014 c) Jardiance® (empagliflozin) label (August 2014). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204629s000lbl.pdf (accessed 10 March 2015).
65. US Food and Drug Administration (2015) Glyxambi® (empagliflozin and linagliptin) label (January 2015). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206073s000lbl.pdf (accessed 10 March 2015).
66. Vasilakou D. Karagiannis T. Athanasiadou E. Mainou M. Liakos A. Bekiari E. et al. (2013) Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159: 262–274.
67. Wright E. Loo D. Hirayama B. (2011) Biology of human sodium glucose transporters. Physiol Rev 91: 733–794.
68. Yale J. Bakris G. Cariou B. Yue D. David-Neto E. Xi L. et al. (2013) Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15: 463–473.
69. Zhang M. Zhang L. Wu B. Song H. An Z. Li S. (2014) Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev 30: 204–221.
70. Zinman B. Inzucchi S. Lachin J. Wanner C. Ferrari R. Fitchett D. et al. (2014) Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOMETM). Cardiovasc Diabetol 13: 102.